Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SB41
- Development stage
- Preclinical
- Lead developer
- Samsung Bioepis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SB41 is an investigational biosimilar candidate referencing AstraZeneca's Fasenra (benralizumab). It is being developed by Samsung Bioepis in partnership with Teva under a global license, development, and commercialization agreement. SB41 is a monoclonal antibody designed to target the interleukin-5 receptor subunit alpha (IL-5Rα), thereby blocking IL-5 signaling and reducing eosinophil levels. The reference product, Fasenra, is approved for the treatment of severe eosinophilic asthma. Under the terms of their partnership, Samsung Bioepis is responsible for the development, regulatory registration, and manufacturing of SB41, while Teva is responsible for commercialization in major global markets, including the United States, Europe, and Canada.
- Other names
- benralizumab biosimilar
02
Targets
IL5RA (Interleukin-5 receptor subunit alpha)
Beyond the preview
Go deeper on SB41.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SB41.